Ocular manifestations in Gorlin-Goltz syndrome.


Journal

Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602

Informations de publication

Date de publication:
18 09 2019
Historique:
received: 03 07 2019
accepted: 04 09 2019
entrez: 20 9 2019
pubmed: 20 9 2019
medline: 1 7 2020
Statut: epublish

Résumé

Gorlin-Goltz syndrome, also known as nevoid basal cell carcinoma syndrome, is a rare genetic disorder that is transmitted in an autosomal dominant manner with complete penetrance and variable expressivity. It is caused in 85% of the cases with a known etiology by pathogenic variants in the PTCH1 gene, and is characterized by a wide range of developmental abnormalities and a predisposition to multiple neoplasms. The manifestations are multiple and systemic and consist of basal cell carcinomas in various regions, odontogenic keratocistic tumors and skeletal anomalies, to name the most frequent. Despite the scarce medical literature on the topic, ocular involvement in this syndrome is frequent and at the level of various ocular structures. Our study focuses on the visual apparatus and its annexes in subjects with this syndrome, in order to better understand how this syndrome affects the ocular system, and to evaluate with greater accuracy and precision the nature of these manifestations in this group of patients. Our study confirms the presence of the commonly cited ocular findings in the general literature regarding the syndrome [hypertelorism (45.5%), congenital cataract (18%), nystagmus (9%), colobomas (9%)] and highlights strabismus (63% of the patients), epiretinal membranes (36%) and myelinated optic nerve fiber layers (36%) as the most frequent ophthalmological findings in this group of patients. The presence of characteristic and frequent ocular signs in the Gorlin- Goltz syndrome could help with the diagnostic process in subjects suspected of having the syndrome who do not yet have a diagnosis. The ophthalmologist has a role as part of a multidisciplinary team in managing these patients. The ophthalmological follow-up that these patients require, can allow, if necessary, a timely therapy that could improve the visual prognosis of such patients.

Sections du résumé

BACKGROUND
Gorlin-Goltz syndrome, also known as nevoid basal cell carcinoma syndrome, is a rare genetic disorder that is transmitted in an autosomal dominant manner with complete penetrance and variable expressivity. It is caused in 85% of the cases with a known etiology by pathogenic variants in the PTCH1 gene, and is characterized by a wide range of developmental abnormalities and a predisposition to multiple neoplasms. The manifestations are multiple and systemic and consist of basal cell carcinomas in various regions, odontogenic keratocistic tumors and skeletal anomalies, to name the most frequent. Despite the scarce medical literature on the topic, ocular involvement in this syndrome is frequent and at the level of various ocular structures. Our study focuses on the visual apparatus and its annexes in subjects with this syndrome, in order to better understand how this syndrome affects the ocular system, and to evaluate with greater accuracy and precision the nature of these manifestations in this group of patients.
RESULTS
Our study confirms the presence of the commonly cited ocular findings in the general literature regarding the syndrome [hypertelorism (45.5%), congenital cataract (18%), nystagmus (9%), colobomas (9%)] and highlights strabismus (63% of the patients), epiretinal membranes (36%) and myelinated optic nerve fiber layers (36%) as the most frequent ophthalmological findings in this group of patients.
CONCLUSIONS
The presence of characteristic and frequent ocular signs in the Gorlin- Goltz syndrome could help with the diagnostic process in subjects suspected of having the syndrome who do not yet have a diagnosis. The ophthalmologist has a role as part of a multidisciplinary team in managing these patients. The ophthalmological follow-up that these patients require, can allow, if necessary, a timely therapy that could improve the visual prognosis of such patients.

Identifiants

pubmed: 31533758
doi: 10.1186/s13023-019-1190-6
pii: 10.1186/s13023-019-1190-6
pmc: PMC6749644
doi:

Substances chimiques

PTCH1 protein, human 0
Patched-1 Receptor 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

218

Références

Oncogene. 2001 Nov 22;20(53):7770-8
pubmed: 11753655
Ophthalmology. 2003 Jan;110(1):34-40
pubmed: 12511343
Nat Genet. 1996 Jan;12(1):85-7
pubmed: 8528259
Lancet. 1992 Mar 7;339(8793):581-2
pubmed: 1347096
Nature. 1996 Nov 14;384(6605):176-9
pubmed: 8906794
Clin Genet. 1999 Jan;55(1):34-40
pubmed: 10066029
Am J Ophthalmol. 2005 Aug;140(2):288-94
pubmed: 16023066
Ophthalmologica. 1990;200(2):77-83
pubmed: 2338989
J Clin Oncol. 2014 Dec 20;32(36):4155-61
pubmed: 25403219
Arch Ophthalmol. 1985 Dec;103(12):1833-6
pubmed: 4074174
Cancer Res. 2006 Feb 15;66(4):2081-8
pubmed: 16489008
Retina. 2018 Sep;38 Suppl 1:S5-S11
pubmed: 29068917
Hum Mol Genet. 2003 Dec 15;12(24):3269-76
pubmed: 14570707
Fam Cancer. 2013 Dec;12(4):611-4
pubmed: 23479190
Hum Mutat. 2006 Mar;27(3):215-9
pubmed: 16419085
J Med Genet. 1993 Jun;30(6):460-4
pubmed: 8326488
Am J Med Genet A. 2010 Feb;152A(2):327-32
pubmed: 20082463
Otolaryngol Clin North Am. 2007 Feb;40(1):113-40, vii
pubmed: 17346564
Br J Cancer. 2006 Aug 21;95(4):548-53
pubmed: 16909134
Nature. 2000 Aug 31;406(6799):1005-9
pubmed: 10984056
Eur J Ophthalmol. 1997 Jan-Mar;7(1):113-4
pubmed: 9101206
Ophthalmic Plast Reconstr Surg. 2006 Jul-Aug;22(4):259-65
pubmed: 16855496
Eye (Lond). 2017 Apr;31(4):636-642
pubmed: 28009345
Scand J Plast Reconstr Surg. 1972;6(2):135-55
pubmed: 4652235
Arch Ophthalmol. 2011 Jan;129(1):69-74
pubmed: 21220631
Acta Crystallogr D Biol Crystallogr. 2013 Dec;69(Pt 12):2563-79
pubmed: 24311597
Am J Med Genet A. 2012 Feb;158A(2):351-7
pubmed: 22246785
Genet Med. 2004 Nov-Dec;6(6):495-502
pubmed: 15545745
J Med Genet. 2017 Aug;54(8):530-536
pubmed: 28596197
Int Ophthalmol. 2005 Feb-Apr;26(1-2):67-72
pubmed: 16786178
J Am Acad Dermatol. 1987 May;16(5 Pt 1):964-70
pubmed: 3584581
Fam Cancer. 2014 Sep;13(3):477-80
pubmed: 24659465
Hum Mol Genet. 2001 Apr;10(7):757-62
pubmed: 11257109
Am J Med Genet. 1994 Apr 15;50(3):282-90
pubmed: 8042673
Int J Oral Maxillofac Surg. 2004 Jul;33(5):458-62
pubmed: 15183409
Br J Neurosurg. 1991;5(6):643-6
pubmed: 1772613

Auteurs

Antonietta Moramarco (A)

Department of Sense Organs, Faculty of Medicine and Odontology, Sapienza University of Rome, Rome, Italy. antonietta.moramarco@uniroma1.it.

Ehud Himmelblau (E)

Department of Sense Organs, Faculty of Medicine and Odontology, Sapienza University of Rome, Rome, Italy. himmelblau50@hotmail.com.

Emanuele Miraglia (E)

Department of Internal Medicine and Medical Specialties, Unit of Dermatology, Sapienza University of Rome, Rome, Italy.

Fabiana Mallone (F)

Department of Sense Organs, Faculty of Medicine and Odontology, Sapienza University of Rome, Rome, Italy.

Vincenzo Roberti (V)

Department of Internal Medicine and Medical Specialties, Unit of Dermatology, Sapienza University of Rome, Rome, Italy.

Federica Franzone (F)

Department of Sense Organs, Faculty of Medicine and Odontology, Sapienza University of Rome, Rome, Italy.

Chiara Iacovino (C)

Department of Internal Medicine and Medical Specialties, Unit of Dermatology, Sapienza University of Rome, Rome, Italy.

Sandra Giustini (S)

Department of Internal Medicine and Medical Specialties, Unit of Dermatology, Sapienza University of Rome, Rome, Italy.

Alessandro Lambiase (A)

Department of Sense Organs, Faculty of Medicine and Odontology, Sapienza University of Rome, Rome, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH